alphaveAUROPHARMA₹1,666.00

Aurobindo Pharma Ltd.

Annual Quarterly₹ CrorePeersSUNPHARMA DRREDDY CIPLA FORTIS LUPIN ALKEM LAURUSLABS MANKINDMcap ₹96,761 Cr

View

In ₹ Crore except Per Share 12 Months Ending	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	7,219.4	7,351.8	7,580.2	7,567.0	7,796.1	7,978.5	8,382.1	7,868.1	8,285.7	8,645.9	8,853.3	9,150.4
Other Income	187.0	162.5	135.6	220.9	136.0	157.3	134.8	105.3	120.6	187.6	117.0	264.2
Total Income	7,406.4	7,514.3	7,715.8	7,788.0	7,932.1	8,135.8	8,516.9	7,973.4	8,406.3	8,833.5	8,970.4	9,414.6
Expenses
+ Cost of Materials Consumed	2,708.9	2,675.5	2,634.9	2,466.7	2,741.9	2,728.7	2,799.5	2,535.2	2,509.8	2,754.9	2,505.4	2,894.4
+ Purchases of Stock-in-Trade	631.1	775.8	786.0	680.0	747.0	823.9	636.2	807.8	846.1	892.7	931.5	931.8
+ Changes in Inventories	-103.2	-300.7	-360.0	-74.0	-278.6	-237.2	-7.8	-103.7	-17.0	-166.3	-7.8	-199.2
+ Employee Benefit Expense	955.0	989.7	1,026.3	1,072.0	1,109.5	1,131.6	1,162.6	1,228.8	1,277.3	1,310.1	1,374.0	1,480.2
+ Finance Costs	68.2	75.6	89.4	111.0	112.7	118.5	115.0	97.8	95.2	92.8	98.2	101.7
+ Depreciation & Amortisation	417.5	423.3	354.3	404.2	382.3	418.5	444.4	405.7	429.2	464.7	478.6	486.8
+ Other Expenses	1,654.3	1,610.2	1,820.1	1,802.8	1,910.2	1,953.6	1,999.7	1,797.1	1,991.4	2,081.3	2,297.5	2,162.2
Total Expenses	6,331.7	6,249.3	6,351.1	6,462.7	6,724.9	6,937.6	7,149.7	6,768.6	7,132.0	7,430.1	7,677.3	7,857.8
EBITDA	1,373.4	1,601.3	1,672.8	1,619.6	1,566.1	1,578.0	1,791.9	1,603.0	1,678.1	1,773.3	1,752.8	1,881.1
EBIT	955.9	1,178.0	1,318.5	1,215.4	1,183.9	1,159.5	1,347.5	1,197.3	1,248.9	1,308.6	1,274.2	1,394.2
Profit
PBT before Exceptional Items	1,074.7	1,265.0	1,364.7	1,325.3	1,207.2	1,198.3	1,367.3	1,204.9	1,274.3	1,403.5	1,293.0	1,556.8
+ Exceptional Items	0.0	0.0	-122.1	0.0	0.0	0.0	0.0	0.0	0.0	-65.3	0.0	-40.2
Pretax Income	1,074.7	1,265.0	1,242.6	1,325.3	1,207.2	1,198.3	1,367.3	1,204.9	1,274.3	1,338.2	1,293.0	1,516.6
+ Current Tax	481.8	384.6	570.6	449.3	322.1	498.1	430.5	490.7	463.0	383.4	399.0	610.0
+ Deferred Tax	-158.1	-62.2	-248.1	-43.6	68.4	-143.8	1.8	-108.1	-35.2	45.4	-29.3	-127.0
Tax Expense	323.7	322.5	322.6	405.7	390.5	354.3	432.3	382.6	427.8	428.7	369.8	483.1
+ Share of Associates & JVs	0.9	-2.6	-12.7	-1.4	0.3	1.6	-32.2	1.9	1.7	0.4	-2.4	-1.5
Net Income	751.9	940.0	907.4	918.2	817.0	845.6	902.8	824.2	848.1	909.8	920.8	1,032.0
+ Net Income — Continuing Ops	751.0	942.6	920.0	919.6	816.7	844.0	935.0	822.3	846.5	909.4	923.3	1,033.6
+ Other Comprehensive Income	51.4	188.7	-110.6	-41.1	270.3	-65.3	139.7	405.8	541.1	227.7	790.6	-46.9
Total Comprehensive Income	803.3	1,128.7	796.8	877.2	1,087.2	780.3	1,042.5	1,230.0	1,389.2	1,137.5	1,711.4	985.2
Net Income to Common	757.2	936.3	908.8	919.2	817.4	854.8	903.5	824.8	848.5	910.3	921.3	1,032.6
Minority Interest	-5.2	3.7	-1.4	-1.0	-0.4	-0.2	-0.6	-0.6	-0.3	-0.5	-0.4	-0.5
Per Share
Basic EPS	12.83	16.04	15.51	15.69	14.00	14.56	15.56	14.20	14.61	15.67	15.86	17.86
Diluted EPS	12.83	16.04	15.51	15.69	14.00	14.56	15.56	14.20	14.61	15.67	15.86	17.86
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	139.7	405.8	541.1	227.7	790.6	-46.9
+ Items NOT to be Reclassified to P&L	-3.5	1.8	-11.1	-0.4	-2.5	-2.1	-3.5	-1.0	0.3	-3.1	14.7	-6.0
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	—	-0.6	-0.3	0.1	-0.6	3.6	0.0
+ Tax on Items NOT to be Reclassified — alt tag	0.6	-0.4	-1.9	-0.1	-0.8	-0.6	—	—	—	—	—	—
+ Items to be Reclassified to P&L	55.5	186.5	-101.4	-40.8	272.0	-63.8	142.5	406.5	540.9	230.2	779.4	-40.9
Comprehensive Income — Owners of Parent	808.6	1,125.0	798.2	878.2	1,087.7	780.5	1,043.1	1,230.6	1,389.5	1,138.0	1,711.8	985.7
Comprehensive Income — Non-controlling Interests	-5.2	3.7	-1.4	-1.0	-0.4	-0.2	-0.7	-0.6	-0.3	-0.5	-0.4	-0.5
Per Share — as-filed variants
Basic EPS — Continuing Operations	12.83	16.04	15.51	15.69	14.00	14.56	15.56	14.20	14.61	15.67	15.86	17.86
Diluted EPS — Continuing Operations	12.83	16.04	15.51	15.69	14.00	14.56	15.56	14.20	14.61	15.67	15.86	17.86
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	3,982.7	4,201.2	4,519.3	4,494.3	4,585.8	4,663.1	4,954.2	4,628.9	4,946.8	5,164.7	5,424.3	5,523.4
Gross Margin %	55.17	57.15	59.62	59.39	58.82	58.45	59.10	58.83	59.70	59.74	61.27	60.36
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	1,074.7	1,265.0	1,364.7	1,325.3	1,207.2	1,198.3	1,367.3	1,204.9	1,274.3	1,403.5	1,293.0	1,556.8
− Exceptional Items (reconciliation)	0.0	0.0	-122.1	0.0	0.0	0.0	0.0	0.0	0.0	-65.3	0.0	-40.2
Net Income Adj (tax-effected)	751.9	940.0	997.8	918.2	817.0	845.6	902.8	824.2	848.1	954.2	920.8	1,059.4
EPS Adj	12.83	16.04	17.06	15.69	14.00	14.56	15.56	14.20	14.61	16.43	15.86	18.33
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Paid Up Equity Capital	58.6	58.6	58.6	58.6	58.1	58.1	58.1	58.1	58.1	58.1	58.1	57.5

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.